Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti CD3 and anti HER2 bispecific T cell engagers - Adagene

Next Previous
Drug Profile

Research programme: anti CD3 and anti HER2 bispecific T cell engagers - Adagene

Alternative Names: CD3 bispecific T-cell engager programme - Adagene; HER2xCD3 SAFE bsAb - Adagene; Her2xCD3 SAFE-bispecific antibodies - Adagene; Her2xCD3 SAFE-bsAbs - Adagene; Her2XCD3 T cell engagers - Adagene; SAFEbody Her2xCD3 BsAb T-cell Engager Programme - Adagene

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adagene
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for preclinical development in Cancer in China (IV)
  • 19 Sep 2021 Research programme: anti CD3 and anti HER2 bispecific T cell engagers - Adagene is available for licensing as of 19 Sep 2021. https://www.adagene.com/contact/
  • 26 Aug 2021 Adagene announces intention to file IND application for Cancer in 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top